Plasma Proteomics for Epidemiology: Increasing Throughput With Standard-Flow Rates

Background— Mass spectrometry is selective and sensitive, permitting routine quantification of multiple plasma proteins. However, commonly used nanoflow liquid chromatography (LC) approaches hamper sample throughput, reproducibility, and robustness. For this reason, most publications using plasma proteomics to date are small in study size. Methods and Results— Here, we tested a standard-flow LC mass spectrometry (MS) method using multiple reaction monitoring for the application to large epidemiological cohorts. We have reduced the LC-MS run time to almost a third of the nanoflow LC-MS approach. On the basis of a comparison of the quantification of 100 plasma proteins in >1500 LC-MS runs, the SD range of the retention time during continuous operation was substantially lower with the standard-flow LC-MS (<0.05 minutes) compared with the nanoflow LC-MS method (0.26–0.44 minutes). In addition, the standard-flow LC method also offered less variation in protein measurements. However, 5× more sample volume was required to achieve similar sensitivity. Two different commercial multiple reaction monitoring kits and an antibody-based multiplexing kit were used to compare the apolipoprotein measurements in a subset of samples. In general, good agreement was observed between the 2 multiple reaction monitoring kits, but some of the multiple reaction monitoring–based measurements differed from antibody-based assays. Conclusions— The multiplexing capability of LC-MS combined with a standard-flow method increases throughput and reduces the costs of large-scale protein measurements in epidemiological cohorts, but protein rather than peptide standards will be required for defined absolute proteoform quantification.

[1]  C. Borchers,et al.  Multiple Reaction Monitoring (MRM): Principles and Application to Coronary Artery Disease , 2012, Circulation. Cardiovascular genetics.

[2]  Ildikó V. Tóth,et al.  A human APOC3 missense variant and monoclonal antibody accelerate apoC-III clearance and lower triglyceride-rich lipoprotein levels , 2017, Nature Medicine.

[3]  Douglas G. Altman,et al.  Measurement in Medicine: The Analysis of Method Comparison Studies , 1983 .

[4]  Steven W. Taylor,et al.  Quantitative insulin analysis using liquid chromatography-tandem mass spectrometry in a high-throughput clinical laboratory. , 2013, Clinical chemistry.

[5]  S. Grebe,et al.  LC-MS/MS in the Clinical Laboratory - Where to From Here? , 2011, The Clinical biochemist. Reviews.

[6]  Susan E. Abbatiello,et al.  Targeted Peptide Measurements in Biology and Medicine: Best Practices for Mass Spectrometry-based Assay Development Using a Fit-for-Purpose Approach* , 2014, Molecular & Cellular Proteomics.

[7]  Michael J. Walker,et al.  A Label-free Selected Reaction Monitoring Workflow Identifies a Subset of Pregnancy Specific Glycoproteins as Potential Predictive Markers of Early-onset Pre-eclampsia* , 2013, Molecular & Cellular Proteomics.

[8]  Ruedi Aebersold,et al.  Quantitative variability of 342 plasma proteins in a human twin population , 2015 .

[9]  N. Anderson,et al.  A List of Candidate Cancer Biomarkers for Targeted Proteomics , 2006, Biomarker insights.

[10]  G. Jarvik,et al.  Parallel reaction monitoring (PRM) and selected reaction monitoring (SRM) exhibit comparable linearity, dynamic range and precision for targeted quantitative HDL proteomics. , 2015, Journal of proteomics.

[11]  Bruno Domon,et al.  Large-Scale Targeted Proteomics Using Internal Standard Triggered-Parallel Reaction Monitoring (IS-PRM)* , 2015, Molecular & Cellular Proteomics.

[12]  F. Kronenberg,et al.  Lipoprotein(a): resurrected by genetics , 2013, Journal of internal medicine.

[13]  T. Pearson,et al.  High precision quantification of human plasma proteins using the automated SISCAPA Immuno-MS workflow. , 2016, New biotechnology.

[14]  C. Borchers,et al.  Comparison of standard- and nano-flow liquid chromatography platforms for MRM-based quantitation of putative plasma biomarker proteins , 2012, Analytical and Bioanalytical Chemistry.

[15]  N. Rifai,et al.  Use of a reference material proposed by the International Federation of Clinical Chemistry and Laboratory Medicine to evaluate analytical methods for the determination of plasma lipoprotein(a). , 2000, Clinical chemistry.

[16]  T. Spector,et al.  Lipidomics Profiling and Risk of Cardiovascular Disease in the Prospective Population-Based Bruneck Study , 2014, Circulation.

[17]  Jeffrey R. Whiteaker,et al.  Sequential Multiplexed Analyte Quantification Using Peptide Immunoaffinity Enrichment Coupled to Mass Spectrometry* , 2011, Molecular & Cellular Proteomics.

[18]  Andreas Stengel,et al.  The importance of using the optimal plasticware and glassware in studies involving peptides. , 2011, Analytical biochemistry.

[19]  Xiaoke Yin,et al.  Very-Low-Density Lipoprotein–Associated Apolipoproteins Predict Cardiovascular Events and Are Lowered by Inhibition of APOC-III , 2017, Journal of the American College of Cardiology.

[20]  Leigh Anderson Six decades searching for meaning in the proteome. , 2014, Journal of proteomics.

[21]  L. Holdt,et al.  Variability of linezolid concentrations after standard dosing in critically ill patients: a prospective observational study , 2014, Critical Care.

[22]  S. Carr,et al.  Quantitative analysis of peptides and proteins in biomedicine by targeted mass spectrometry , 2013, Nature Methods.

[23]  G. Nicol,et al.  Reversed-phase high-performance liquid chromatographic prefractionation of immunodepleted human serum proteins to enhance mass spectrometry identification of lower-abundant proteins. , 2005, Journal of proteome research.

[24]  Christoph H Borchers,et al.  Multi-site assessment of the precision and reproducibility of multiple reaction monitoring–based measurements of proteins in plasma , 2009, Nature Biotechnology.

[25]  Leigh Anderson,et al.  Quantitative Mass Spectrometric Multiple Reaction Monitoring Assays for Major Plasma Proteins* , 2006, Molecular & Cellular Proteomics.

[26]  Juncong Yang,et al.  MRM‐based multiplexed quantitation of 67 putative cardiovascular disease biomarkers in human plasma , 2012, Proteomics.

[27]  N. Anderson,et al.  The Human Plasma Proteome: History, Character, and Diagnostic Prospects , 2003, Molecular & Cellular Proteomics.

[28]  Darryl B. Hardie,et al.  Mass spectrometric quantitation of peptides and proteins using Stable Isotope Standards and Capture by Anti-Peptide Antibodies (SISCAPA). , 2004, Journal of proteome research.

[29]  Zeneng Wang,et al.  Intestinal Microbial Metabolism of Phosphatidylcholine and Cardiovascular Risk , 2013 .

[30]  Matthias Mann,et al.  Plasma Proteome Profiling to Assess Human Health and Disease. , 2016, Cell systems.

[31]  Amanda G. Paulovich,et al.  An Automated and Multiplexed Method for High Throughput Peptide Immunoaffinity Enrichment and Multiple Reaction Monitoring Mass Spectrometry-based Quantification of Protein Biomarkers* , 2009, Molecular & Cellular Proteomics.

[32]  J. Garin,et al.  Production and use of stable isotope-labeled proteins for absolute quantitative proteomics. , 2011, Methods in molecular biology.

[33]  T. Pearson,et al.  Multiplexed longitudinal measurement of protein biomarkers in DBS using an automated SISCAPA workflow. , 2016, Bioanalysis.

[34]  T. Annesley Ion suppression in mass spectrometry. , 2003, Clinical chemistry.

[35]  Chris Sander,et al.  Human SRMAtlas: A Resource of Targeted Assays to Quantify the Complete Human Proteome , 2016, Cell.

[36]  Ruedi Aebersold,et al.  Reproducible Quantification of Cancer-Associated Proteins in Body Fluids Using Targeted Proteomics , 2012, Science Translational Medicine.

[37]  N. Spooner,et al.  Reduction of signal suppression effects in ESI-MS using a nanosplitting device. , 2001, Analytical chemistry.